CN104402865A - 一种埃索美拉唑镁杂质d的制备方法 - Google Patents
一种埃索美拉唑镁杂质d的制备方法 Download PDFInfo
- Publication number
- CN104402865A CN104402865A CN201410616257.XA CN201410616257A CN104402865A CN 104402865 A CN104402865 A CN 104402865A CN 201410616257 A CN201410616257 A CN 201410616257A CN 104402865 A CN104402865 A CN 104402865A
- Authority
- CN
- China
- Prior art keywords
- reaction
- hydrogen peroxide
- esomeprazole
- preparation
- impurity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- VSOAYQZFYNZNKR-UHFFFAOYSA-N 2-[(6-methoxy-1h-benzimidazol-2-yl)sulfinylmethyl]-3,5-dimethyl-1h-pyridin-4-one Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(O)=C1C VSOAYQZFYNZNKR-UHFFFAOYSA-N 0.000 title abstract 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 69
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 58
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 42
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000001953 recrystallisation Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 37
- 238000003756 stirring Methods 0.000 claims description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 229960000197 esomeprazole magnesium Drugs 0.000 claims description 26
- KWORUUGOSLYAGD-WLHYKHABSA-N magnesium;5-methoxy-2-[(r)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-WLHYKHABSA-N 0.000 claims description 26
- 239000012074 organic phase Substances 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- 229960000583 acetic acid Drugs 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000003205 fragrance Substances 0.000 claims description 14
- 239000012362 glacial acetic acid Substances 0.000 claims description 14
- 150000003851 azoles Chemical class 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 10
- 238000009413 insulation Methods 0.000 claims description 7
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 3
- 238000004886 process control Methods 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 13
- 238000000605 extraction Methods 0.000 abstract description 10
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract description 7
- 229960000381 omeprazole Drugs 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 abstract description 4
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 abstract description 3
- 239000013558 reference substance Substances 0.000 abstract description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 2
- 230000003197 catalytic effect Effects 0.000 abstract description 2
- 229960004770 esomeprazole Drugs 0.000 abstract description 2
- 239000011777 magnesium Substances 0.000 abstract description 2
- 229910052749 magnesium Inorganic materials 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 159000000000 sodium salts Chemical class 0.000 abstract description 2
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 239000007810 chemical reaction solvent Substances 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 239000012043 crude product Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 238000012423 maintenance Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 7
- 239000012535 impurity Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410616257.XA CN104402865B (zh) | 2014-10-26 | 2014-10-26 | 一种埃索美拉唑镁杂质d的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410616257.XA CN104402865B (zh) | 2014-10-26 | 2014-10-26 | 一种埃索美拉唑镁杂质d的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104402865A true CN104402865A (zh) | 2015-03-11 |
CN104402865B CN104402865B (zh) | 2019-06-14 |
Family
ID=52640545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410616257.XA Active CN104402865B (zh) | 2014-10-26 | 2014-10-26 | 一种埃索美拉唑镁杂质d的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104402865B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107987058A (zh) * | 2017-11-28 | 2018-05-04 | 江苏中邦制药有限公司 | 一种艾司奥美拉唑钠杂质i的合成方法 |
CN108250181A (zh) * | 2017-11-28 | 2018-07-06 | 江苏中邦制药有限公司 | 一种制备埃索美拉唑杂质d的方法 |
CN109928954A (zh) * | 2017-12-19 | 2019-06-25 | 鲁南制药集团股份有限公司 | 一种埃索美拉唑钠杂质的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458146A (zh) * | 2002-05-15 | 2003-11-26 | 中国科学院上海药物研究所 | 抗肿瘤药物比卡鲁胺合成工艺 |
-
2014
- 2014-10-26 CN CN201410616257.XA patent/CN104402865B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458146A (zh) * | 2002-05-15 | 2003-11-26 | 中国科学院上海药物研究所 | 抗肿瘤药物比卡鲁胺合成工艺 |
Non-Patent Citations (2)
Title |
---|
袁志法: "吲哚基苯并咪唑类化合物的合成及其抑制胃酸活性的研究", 《中国优秀硕士学位论文数据库(医药卫生科技辑)》 * |
郝玲花 等: "奥美拉唑产品中二种杂质的制备", 《中国医药工业杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107987058A (zh) * | 2017-11-28 | 2018-05-04 | 江苏中邦制药有限公司 | 一种艾司奥美拉唑钠杂质i的合成方法 |
CN108250181A (zh) * | 2017-11-28 | 2018-07-06 | 江苏中邦制药有限公司 | 一种制备埃索美拉唑杂质d的方法 |
CN109928954A (zh) * | 2017-12-19 | 2019-06-25 | 鲁南制药集团股份有限公司 | 一种埃索美拉唑钠杂质的制备方法 |
CN109928954B (zh) * | 2017-12-19 | 2021-08-31 | 鲁南制药集团股份有限公司 | 一种埃索美拉唑钠杂质的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104402865B (zh) | 2019-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105330609B (zh) | 一种制备lcz696的方法 | |
CN104402865A (zh) | 一种埃索美拉唑镁杂质d的制备方法 | |
CN107417515A (zh) | 一种合成达格列净中间体的新方法 | |
CN106478437A (zh) | 一种γ‑氨基戊酸酯衍生物的制备方法 | |
CN104326881A (zh) | 3,5-二甲基-4-氯苯酚的制备方法 | |
CN104151164A (zh) | 一种制取氯乙酸甲酯的方法 | |
CN102584692B (zh) | 盐酸吡哆醇的制备方法 | |
CN101225073B (zh) | 一种离子液体及制备方法及在生物转酯合成中的应用 | |
CN106916109B (zh) | 一种质子化吡唑类离子液体及利用其催化合成环状碳酸酯的方法 | |
CN103044468B (zh) | N-(2-吡嗪羰基)-l-苯丙氨酸-l-亮氨酸硼酸的制备方法 | |
CN102351790B (zh) | 7-溴-6-氯-4(3h)-喹诺酮的合成方法 | |
CN105330560A (zh) | 一种恩杂鲁胺中间体的制备方法 | |
CN107778175A (zh) | 1,4‑环己烷二甲醇二异辛酸酯的合成工艺 | |
CN103113250A (zh) | 一种d-对羟基苯甘氨酸甲酯的制备方法 | |
CN105294797A (zh) | 一种甲睾酮的制备方法 | |
CN105367535B (zh) | 一种绿色催化合成1,8‑二氧代‑十氢吖啶衍生物的方法 | |
CN104193674A (zh) | 一种氟尼辛葡甲胺的合成方法 | |
CN104326915A (zh) | 改性金属氧化物型固体超强酸催化合成对羟基苯甲酸乙酯的方法 | |
CN101050206A (zh) | 一种制备瑞格列奈的方法 | |
CN202912870U (zh) | 一种用于生产丁二酸二甲酯的装置 | |
CN113336749B (zh) | 一种吲哚并喹啉类化合物的制备方法 | |
CN106588610A (zh) | 一种制备甜瓜醛的方法 | |
CN103044315A (zh) | 一种以酸性离子液体为催化剂制备1,4-二氢吡啶的方法 | |
CN106831549A (zh) | 一种抗过敏药物卡比沙明的不对称合成方法 | |
CN106167465B (zh) | 一种依达拉奉二聚体杂质化合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180205 Address after: Tianrun road Wendeng Economic Development Zone in Weihai City, Shandong Province, No. 268 264400 Applicant after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 Shandong province Weihai Jing District Qilu Avenue - No. 55-1 scientific research building 201 Applicant before: WEIHAI YARUI BIOLOGICAL SCIENCE & TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191107 Address after: 264205 Guangzhou East Road South and an East Road East, Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Co-patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Co-patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tianrun road Wendeng Economic Development Zone in Weihai City, Shandong Province, No. 268 264400 Co-patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210611 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |